

1 **Title:** Associations of Adipokine Levels with Levels of Remnant Cholesterol: the Multi-Ethnic
2 Study of Atherosclerosis (MESA)

3 **Short Title:** Adipokines and Remnant Cholesterol

4 **Authors:** Renato Quispe, MD MHS¹, Ty Sweeney, MD¹, Seth S. Martin MD, MHS¹, Steven R.
5 Jones MD¹, Matthew A. Allison, MD, MPH,² Matthew J. Budoff, MD³, Chiadi E. Ndumele,
6 MD, PhD¹, Mohamed B. Elshazly, MD⁴, Erin D. Michos, MD, MHS¹

7
8 **Affiliations:**

- 9 1. Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University
10 School of Medicine, Baltimore, MD
11 2. Department of Family Medicine, University of California San Diego, San Diego, CA
12 3. Lundquist Institute, Los Angeles, CA
13 4. Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic,
14 Cleveland, OH

15 **Word count**

16 **Abstract:** 250 (limit 250)

17 **Main text:** 3247

18 **References:** 56

19 **Tables:** 5; **Figures:** 3

20 **Supplemental Tables:** 2

21
22 **Corresponding author**

23 Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC

24 Associate Professor of Medicine

25 Division of Cardiology

26 Johns Hopkins University School of Medicine

27 Blalock 524-B, 600 N. Wolfe Street, Baltimore, MD, 21287

28 Phone: 410-502-6813; Email: edonnell@jhmi.edu; Twitter: [@ErinMichos](https://twitter.com/ErinMichos)

29

30

31 **ABSTRACT**

32 **Background**

33 The metabolic syndrome phenotype of individuals with obesity is characterized by elevated
34 levels of triglyceride (TG)-rich lipoproteins and remnant particles, which have been shown to be
35 significantly atherogenic. Understanding the association between adipokines, endogenous
36 hormones produced by adipose tissue, and remnant cholesterol (RC) would give insight into the
37 link between obesity and atherosclerotic cardiovascular disease.

38
39 **Methods**

40 We studied 1,791 MESA participants of an ancillary study on body composition who had
41 adipokine levels measured (leptin, adiponectin, resistin) at either visit 2 or 3. RC was calculated
42 as non-high density lipoprotein cholesterol minus low-density lipoprotein cholesterol (LDL-C),
43 measured at the same visit as the adipokines, as well as subsequent visits 4 through 6.
44 Multivariable-adjusted linear mixed effects models were used to assess the cross-sectional and
45 longitudinal associations between adipokines and levels of RC.

46
47 **Results**

48 Mean (SD) age was 64.5±9.6 years and for body mass index (BMI) was 29.9±5.0 kg/m²; 52.0%
49 were women. In fully adjusted models that included BMI, LDL-C and lipid-lowering therapy, for
50 each 1-unit increment in adiponectin, there was 14.4% (12.0, 16.8) lower RC. With each 1-unit
51 increment in leptin and resistin, there was 4.5% (2.3, 6.6) and 5.1% (1.2, 9.2) higher RC,
52 respectively. Lower adiponectin and higher leptin were also associated with longitudinal
53 increases in RC levels over median follow-up of 5(4-8) years.

54
55 **Conclusions**

56 Lower adiponectin and higher leptin levels were independently associated with higher levels of
57 RC at baseline and longitudinal RC increase, even after accounting for BMI and LDL-C.

58
59 **Keywords:** adipokines, remnant cholesterol, obesity

60

61 **CLINICAL PERSPECTIVE**

62

63 **What is new?**

64

65 - Among individuals without history of cardiovascular disease, adiponectin is inversely
66 associated with cross-sectional levels of remnant cholesterol, whereas leptin and resistin are
67 directly associated.

68 - Adiponectin had an inverse association with progression of remnant cholesterol levels over
69 time.

70

71 **What are the clinical implications?**

72 - Adiponectin levels were not associated with LDL-C levels but with levels of triglyceride-rich
73 lipoproteins, particularly remnant cholesterol.

74 -Incrementing adiponectin via lifestyle modification and/or pharmacological therapies (i.e. GLP-
75 1 agonists) could be a mechanism to reduce remnant cholesterol levels and ultimately
76 cardiovascular risk.

77

78 INTRODUCTION

79 Obesity is one of the most important risk factors for development of atherosclerotic
80 cardiovascular disease (ASCVD)¹⁻³ and it is projected that 1 in 2 U.S. adults will be classified as
81 having obesity (defined by a body mass index (BMI) ≥ 30 kg/m²) by 2030.⁴ The
82 pathophysiologic link between obesity and ASCVD is not fully understood.⁵ In this regard, the
83 metabolic syndrome lipid phenotype of individuals with obesity is often characterized by
84 elevation of triglyceride (TG) levels and low levels of high density lipoprotein cholesterol (HDL-
85 C).⁶

86 Mounting evidence from the last decade has shown the role of TG and TG-rich
87 lipoproteins (TGRL) in the development of ASCVD.⁷ Remnant lipoprotein particles (RLPs) are
88 partially lipolysed lipoproteins derived from TGRL of both liver [very low-density lipoprotein,
89 (VLDL)] and intestinal (chylomicron) origins,⁸ which have been shown to contribute to
90 atherosclerosis independent of, and additional to, low-density lipoprotein cholesterol (LDL-C).⁹
91 ¹⁰ These remnant particles contain a large amount of cholesterol and contribute to endothelial
92 dysfunction, inflammation and ultimately atherogenesis.^{7, 11} Interestingly, elevated levels of
93 remnant cholesterol are strongly associated with higher ratios of TG to HDL-C,¹² which are often
94 encountered among individuals with obesity and metabolic syndrome. The association between
95 remnant cholesterol (RC) and ASCVD has been established by genetic^{13, 14} as well as
96 observational studies.^{15, 16}

97 Adipokines, such as leptin, adiponectin and resistin, are endogenous hormones that are
98 released from adipose tissue or adjacent inflammatory cells and have been shown to influence
99 several metabolic processes such as insulin sensitivity, endothelial function and appetite
100 regulation.¹⁷⁻²¹ However, the association of adipokines with levels of RC has not been fully

101 elucidated, as well as the role of different adipokines in the prediction of change in RC levels. In
102 the analysis described below, we evaluated the associations between endogenous adipokines and
103 1) cross-sectional levels of RC; and 2) progression of RC levels over time.

104

105 **METHODS**

106 **Study population**

107 The Multi-Ethnic Study of Atherosclerosis (MESA) cohort enrolled 6,814 men and women
108 aged 45 to 84 years who were free of CVD at baseline (2000-2002). Adipokine levels and the
109 computed tomography (CT) assessment of visceral and subcutaneous adipose tissue (VAT and
110 SAT) were measured as part of an ancillary study in 1,970 men and women at either visit 2 or visit
111 3 (randomly assigned). The baseline for this analysis was the time of the adipokine measurement
112 (either visit 2 or 3). We included all MESA participants who had endogenous adipokines (leptin,
113 adiponectin, resistin) and a standard lipid panel obtained at either visit 2 or 3. For the primary
114 cross-sectional analysis, we used the lipid panel that was at the same visit as the adipokine
115 measurements, but for longitudinal analysis, we also used lipid panels from subsequent visits.
116 Individuals with missing data on the exposure variables, the outcome variables, or the covariates
117 in our model were excluded (n=179), leaving a primary analytical sample of 1,791 individuals.

118 **Independent variables assessment**

119 The primary independent variables were levels of the endogenous adipokines (leptin,
120 adiponectin, and resistin) and their ratios (leptin/adiponectin and resistin/adiponectin). Samples of
121 fasting serum were obtained at either visit 2 (2002-2004) or visit 3 (2004-2005), at the visit of the
122 abdominal CT scan,²²⁻²⁴ and immediately frozen at -70°C. In 2009, the adipokines (adiponectin,
123 leptin, and resistin) were measured from these stored serum samples using a Bio-Rad Luminex

124 flow cytometry (Millipore, Billerica, MA) at the Laboratory for Clinical Biochemistry Research
125 (University of Vermont, Burlington, VT), as previously reported.^{25, 26} The coefficients of variation
126 for these assays ranged from 6 to 13%.

127 **Dependent variables assessment**

128 From a standard lipid panel, RC levels were estimated as non-HDL-C *minus* LDL-C. LDL-
129 C was estimated using the Martin/Hopkins equation. This method estimates LDL-C using 1 of 174
130 different factors for the TG to VLDL-C ratio according to non-HDL-C and TG levels when TG
131 levels are <400 mg/dL.²⁷ We additionally performed similar estimation when TG levels were 400-
132 799 mg/dL using an expanded version of the Martin/Hopkins method that uses several more factors
133 with increased accuracy.²⁸ Our group has previously shown that this estimation method for RC
134 levels is more accurate than using the Friedewald equation.²⁹

135 **Covariates**

136 The covariates included in this study include the following demographic, behavioral and
137 ASCVD risk factors measured at the visit of the adipokine assessment: age, sex, race/ethnicity,
138 study site, education (<high school; high school or vocational school; college, graduate or
139 professional school), cigarette smoking status (current, former or never), physical activity (MET
140 hrs/week of moderate or vigorous activity, continuous), BMI (in kg/m²), total cholesterol (mg/dL),
141 HDL-C (mg/dL), use of lipid lowering medications (yes/no), diabetes (defined as fasting blood
142 sugar \geq 126 on non-fasting glucose \geq 200 mg/dl or medication use), and measures of abdominal
143 body composition (VAT and SAT) by CT. In exploratory models, we replaced BMI with VAT and
144 SAT measures from abdominal CTs from visits 2/3. We also explored new use of lipid lowering
145 medications during follow-up at visits 4, 5 and 6.

146 **Statistical analysis**

147 We described the baseline demographics and clinical characteristics of the study
148 participants at the time of their adipokine level measurement, stratified by tertiles of each
149 adipokine (adiponectin, leptin and resistin, separately). Continuous variables were expressed as
150 mean and standard deviations (SD) and categorical variables as frequency and percentages. For
151 our regression models, both RC and adipokine levels and their ratios were log-transformed given
152 their non-normal distribution. The regression results were then exponentiated and shown as percent
153 differences using the following formula: $(e^{\beta}-1)*100$.

154 Our primary outcome was RC levels (estimated as described above) assessed cross-
155 sectionally at visits 2 or 3. Our secondary outcome was the prospective change in RC levels from
156 the time of measurement of adipokines (either visit 2 or 3) to Exam 6. We used standard lipid
157 panels from visits 2, 3, 4, 5, and 6 to leverage all available lipid panels in mixed effects linear
158 regression models.

159 We assessed the longitudinal change in RC levels associated with each of the adipokine
160 levels separately by using multivariable-adjusted linear mixed effects models allowing for random
161 variations in baseline RC levels and longitudinal slope for RC progression across participants. The
162 mixed effects model for longitudinal data leverages all available lipid panel (RC) information from
163 all participants, including those without follow-up measurements, to jointly model the level of RC
164 at baseline and RC change over time. In this mixed effect model, cross-sectional associations are
165 represented by coefficients of the adipokines, which estimate the difference in RC at baseline by
166 varying adipokine levels. Longitudinal associations are represented by coefficients of interactions
167 between adipokines and time since baseline, which estimate the rate of change in RC levels
168 associated with adipokines.

169 The linear regression models were progressively adjusted as follows: Model 1 – age, sex,
170 race/ethnicity, and study site; Model 2 – Model 1 + education, smoking status, and physical
171 activity; Model 3 – Model 2 + BMI; Model 4 – Model 3 + LDL-C; Model 5 – Model 4 + use of
172 lipid-lowering therapy; Model 6 – Model 5 + diabetes mellitus; Model 7 - Model 5 + subcutaneous
173 fat area, in cm² (instead of BMI); Model 8 – Model 5 + visceral fat area, in cm² (instead of BMI)
174 For sensitivity analyses, we evaluated interactions by sex, diabetes mellitus and obesity status
175 (BMI \geq 30 vs <30 kg/m²).

176

177 **RESULTS**

178 **Study population**

179 The mean age (SD) of the population was 64.5 (9.6) years, and about half of them were
180 women (52%). In terms of race/ethnicity, the majority of individuals were of White (39.8%),
181 followed by Hispanic (25.5%), Black (21.1%) and Chinese-Americans (13.6%). The mean (SD)
182 BMI of the population was 29.9 (5.0) kg/m². The median (IQR) TG levels were 113 (77-161)
183 mg/dL, and the median (IQR) RC levels were 21.8 (16.9-27.8) mg/dL. The median (IQR) values
184 for adipokines were: adiponectin, 17.5 (11.9-26.4) ng/mL; leptin, 13.1 (5.6-28.2) ng/mL; and
185 resistin, 14.9 (11.9-18.8) ng/mL.

186 **Baseline characteristics by adipokine levels**

187 The baseline characteristics were estimated per tertiles of each adipokines separately to
188 more evenly distribute the population, and are shown in **Table 1** (adiponectin), **Table 2** (leptin),
189 and **Table 3** (resistin).

190 Compared to lower tertiles of adiponectin, we observed significantly higher proportions
191 of females, White individuals and never smokers, but lower proportions of individuals with

192 diabetes mellitus ($p < 0.05$) in the highest tertile of adiponectin. In the highest tertile of
193 adiponectin, we also observed lower levels of both TG and RC, but higher levels of HDL-C. We
194 did not observe significant differences in levels of BMI, TC and LDL-C across adiponectin
195 tertiles (**Table 1**).

196 Compared to lower tertiles of leptin, we observed significantly higher proportions of
197 females, Black and Hispanic individuals, and never smokers in the highest tertile of leptin. We
198 also observed higher proportions of diabetes mellitus, along with greater use of antihypertensive
199 and lipid-lowering medications with higher leptin. With regards to lipid parameters, we observed
200 higher levels of TG and RC in the highest compared to lower leptin tertiles. We found that those
201 in the highest leptin tertile had significantly higher BMI levels compared to lower tertiles
202 ($p < 0.05$). Contrarily, we did not find significant differences in TC and LDL-C across leptin
203 tertiles (**Table 2**).

204 Finally, we found significantly higher BMI levels in the highest compared to lower
205 tertiles of resistin, along with prevalence of diabetes mellitus and use of antihypertensive
206 medications ($p < 0.05$). In the highest resistin tertile, the average TG level was higher and HDL-C
207 was lower, but we did not find any significant differences between lipid parameters, including
208 LDL-C and RC, across tertiles (**Table 3**).

209 **Cross sectional association between adipokines and RC**

210 The associations between adipokines and RC are shown graphically in the figures.
211 **Figure 1** shows an inverse association between adiponectin and RC levels, whereas **Figure 2**
212 shows a direct association between leptin and RC. Levels of resistin appears to be equally
213 dispersed across levels of RC in **Figure 3**.

214 In our cross-sectional linear regression models, we observed that after adjustment for
215 demographic variables (Model 1), each 1-unit increment in adiponectin was associated with a
216 17.3% (14.8, 19.7) lower level of RC, whereas similar 1-unit increments in leptin and resistin
217 were associated with 7.3% (6.2, 9.4) and 6.2% (2.0, 10.5) higher RC levels (**Table 4**). In fully
218 adjusted models that included BMI, LDL-C and lipid-lowering therapy (Model 5), we observed
219 that for each 1-unit increment in adiponectin, RC levels were 14.4% (12.0, 16.8) lower.
220 Conversely, 1-unit increment changes in leptin and resistin were associated with higher RC
221 levels by 4.5% (2.3, 6.6) and 5.1% (1.2, 9.2), respectively. Similar results were observed in
222 models that included subcutaneous (Model 6) and visceral fat area (Model 7) instead of BMI
223 (**Table 4**). We did not find effect modification by sex, diabetes mellitus or obesity (p-value for
224 interaction >0.05).

225 **Longitudinal association between adipokines and RC**

226 Participants were followed for median (IQR) of 5 (4-8) years. In longitudinal analyses we
227 observed that for each 1-unit increment in baseline adiponectin, there was a 14.2% (12.0, 16.4)
228 reduction in RC levels over time after adjusting for demographic and cardiovascular risk factors
229 (Model 2). After further adjusting for other time-varying covariates such as BMI, LDL-C and
230 lipid-lowering therapy (Model 5), we observed a 11.6% (9.5, 13.6) reduction in RC over time.

231 We found a 6.3% (4.8, 7.8) increase in RC over time for each increase in 1-unit of leptin,
232 although this increase was only 1.6-1.8% after further adjusting for BMI, LDL-C, lipid-lowering
233 therapy, and diabetes (Model 4-6, **Table 5**). We did not find significant or clinically relevant
234 associations between resistin levels and longitudinal changes in RC (**Table 5**).

235

236 **DISCUSSION**

237 In this multiethnic cohort of individuals, we observed a significant inverse cross-sectional
238 association between adiponectin and levels of RC, whereas we found a significant but less potent
239 associations of leptin and resistin with levels of RC. In longitudinal analyses, we found that only
240 baseline levels of adiponectin continued to have a strong independent inverse association with
241 RC levels over time, whereas leptin had a more modest association and resistin was not
242 associated with longitudinal change in RC levels.

243 The relationship between TG and ASCVD has been complex and historically difficult to
244 define. It has been shown that individuals with hypertriglyceridemia have increased rates of
245 secretion of TG overloaded very low-density lipoproteins, which then metabolize to small dense
246 LDL particles, which are shown to be highly atherogenic.³⁰ On the other hand, many
247 epidemiologic studies showed a strong role for low HDL-C as a predictor of cardiovascular risk,
248 suggesting it may even be a better predictor than high TG. The association between TG and
249 ASCVD was shown to be attenuated after adjusting for HDL-C. However, TG and HDL-C have
250 a strong inverse association,¹⁴ and it was unclear which of the two was really the culprit for
251 development of ASCVD. Over the past decade, multiple trials of HDL-C raising therapies failed
252 to show a benefit with regards to risk;³¹⁻³³ further, genetic studies^{34, 35} have helped to confirm that
253 HDL-C is not a causal risk factor for ASCVD, but it may rather be a marker of high TG levels.

254 TGRL contain both triglycerides and cholesterol. However, the simplest measurement of
255 TGRL are serum TG and RC, both of which can be easily obtained from the standard lipid
256 panel.³⁶ In order to cause atherosclerosis, TGRL need to enter into the arterial intimal space.
257 However, unlike cholesterol, TG can be degraded by most cells and do not accumulate in the
258 atherosclerotic plaque; for these reasons it has been considered that, pathophysiologically
259 speaking, TG could not be a promoter of atherosclerosis. Instead, it has been suggested that

260 serum/plasma levels of TG should be rather considered as a marker of high levels of cholesterol
261 within TGRL (i.e. RC).³⁶ RC represents the concentration of all plasma cholesterol not found in
262 LDL and HDL; or in other words, in all TGRL. RC has been shown to be associated with events
263 by several observational studies. For instance, we showed that RC was associated with
264 progression of atheroma in a secondary prevention population,¹⁶ as well as incident events
265 independent of LDL-C and apolipoprotein B (apoB) levels in a pooled cohort of individuals free
266 of ASCVD.³⁷ Further, Mendelian randomization studies confirmed the causal role of RC in the
267 development of atherosclerosis.¹⁴

268 To the best of our knowledge, this is the first study evaluating the association between
269 adipokines and remnant cholesterol. In our study we observed that out of the three adipokines
270 that we evaluated, only adiponectin continued to be significantly associated with RC in both
271 cross-sectional and longitudinal analyses with similar results between the two models.
272 Adiponectin is an adipocyte-specific hormone that has been classically shown to be reduced in
273 individuals with obesity, possibly due to several mechanisms including hypoxia, inflammation,
274 and downregulation of β -adrenergic signaling.³⁸⁻⁴⁰ Adiponectin has several systemic insulin-
275 sensitizing and anti-inflammatory properties,⁴¹⁻⁴³ given that its signaling leads to metabolic
276 health-promoting alterations such as decreased hepatic gluconeogenesis, increased fatty acid
277 oxidation in liver and skeletal muscle, protective effect on pancreatic β -cells, and increased
278 glucose uptake in muscle.⁴¹ Adiponectin has also been shown to have anti-inflammatory
279 properties via its effects on TNF-alpha and C-reactive protein⁴⁴ with effects on formation of the
280 atherosclerotic plaque.^{45,46} Thus, taken together, adiponectin is generally thought to be a
281 cardioprotective adipokine. Previous studies have shown that adiponectin levels are negatively
282 correlated with markers of TGRL metabolism, such as apoC-III, VLDL-triglycerides, apoB-48

283 levels. Interestingly, like previous studies,⁴⁷⁻⁴⁹ our findings were independent of presence of
284 diabetes mellitus at baseline. We did find an inverse association between adiponectin and levels
285 of RC; these findings could be explained by three mechanisms based on previous studies from
286 the literature. First, adiponectin may decrease accumulation of TG in skeletal muscle by
287 enhancing fatty acid oxidation;⁵⁰ second, adiponectin can stimulate lipoprotein lipase in the liver
288 and adipocytes;⁵¹ third, adiponectin may decrease the supply of nonesterified fatty acid to the
289 liver for gluconeogenesis which leads to decreased TG synthesis.⁵²

290 Leptin is an adipokine that is almost exclusively expressed in adipocytes; it has been
291 proposed that the most important physiologic role of leptin is via appetite suppression and
292 promoting energy expenditure through receptors in the central nervous system. Circulating leptin
293 levels have been shown to correlate positively with adipose tissue mass,⁵³ as we observed in our
294 study. However, other physiologic roles of leptin are not well established or understood. For
295 instance, it has been also suggested that leptin signaling also occurs in pancreatic β -cells with
296 some in-vitro studies showing that leptin signaling inhibits insulin secretion and increases
297 survival of β -cells.^{54,55} However, these findings have not been confirmed with in-vivo studies:
298 mouse models with LEPR knockdown restricted to β -cells found no evidence of
299 hyperinsulinemia or disturbed glucose hemostasis.⁵⁶ In a prior MESA analysis, leptin levels were
300 not found to be independently associated with ASCVD after accounting for BMI.⁵⁷ In our study,
301 we found an increasing prevalence of diabetes mellitus at higher leptin levels, which could be
302 due to greater adiposity as reflected by higher BMI. Higher levels of TG and RC in the highest
303 tertile of leptin could be due to the greater prevalence of diabetes mellitus rather than a direct
304 effect of leptin; indeed the association between leptin and longitudinal change in RC was rather
305 weak and probably not clinically relevant.

306 Resistin, an adipokine released by tissue-resident macrophages rather than adipocytes,
307 accelerates insulin resistance and the development of inflammatory metabolic diseases.
308 However, no specific receptor has been identified so far, so the mechanism of this adipokine is
309 not fully understood. We did not identify significant longitudinal associations between resistin
310 levels and TG and/or RC, for which we hypothesize that the metabolic effect of resistin may not
311 be related to TGRL.

312 **Strengths and Limitations**

313 Our study has several strengths. First, we used the definition of non-HDL-C minus
314 Martin/Hopkins LDL-C given its availability from the standard lipid panel at no extra cost and
315 superiority when compared with RC extrapolated from Friedewald LDL-C.²⁹ This estimation
316 method has been used by most studies in the literature, and includes both atherogenic remnant
317 particles and large non-atherogenic particles such as large VLDL. Second, we were able to adjust
318 for other markers of adiposity, particularly VAT which has been proposed to be a more accurate
319 marker of abdominal obesity compared to waist circumference and BMI; furthermore, it has been
320 proposed that visceral adiposity is the primary source of adipokines.⁵⁸ Third, three of the most
321 important and clinically relevant adipokines were included in this study, and they were measured
322 by standardized and reproducible methods. Fourth, we were able to obtain data from subsequent
323 visits after baseline in a time-varying fashion, such as BMI, LDL-C, age, smoking status and use
324 of lipid-lowering therapies. Fifth, we were able to perform mixed effect models to model RC
325 change over time, which has more statistical power than cross-sectional analysis.

326 Our study has some limitations. First, given the observational nature of the study design,
327 we cannot rule out the presence of residual confounding by unmeasured covariates. Second,
328 adipokines were only measured once (either visit 2 or 3), for which we were not able to evaluate

329 the association between change in adipokines over time and RC over time. It should be
330 considered that RLP can also induce proinflammatory cytokines released from adipocytes and
331 decreased adiponectin secretion by activating NF-kB and JNK pathways⁵⁹ or induce
332 adipogenesis in an apoE-dependent manner⁶⁰ leading to an increase in the amount of adipose
333 tissue. Therefore, it may not be possible to fully distinguish the direction of the association
334 between adipokines and RC. Third, the sample size of our study was relatively small for which
335 stratified analyses were not sufficiently powered to detect significant differences.

336

337 **Conclusion**

338 Lower adiponectin and higher leptin levels were associated with worse metabolic profile,
339 and associated with higher levels of remnant cholesterol independent of traditional risk factors
340 including obesity markers. Additionally, adiponectin levels were significantly independently
341 inversely associated with changes in RC over time, whereas leptin levels were modestly
342 positively associated with longitudinal increase in RC. These findings might help explain the link
343 between obesity and ASCVD pathogenesis.

344

345 **Disclosures:**

346 Unrelated to this work, Dr. Michos served as a consultant for Amgen, Amarin, AstraZeneca,
347 Bayer, Boehringer Ingelheim, Edwards Life Science, Esperion, Medtronic, Novartis, Novo
348 Nordisk, and Pfizer. She is a co-investigator on a grant funded by Merck. Outside of this work,
349 Dr. Martin reports consulting fees from Amgen, AstraZeneca, Bristol Myers Squibb, Dalcour,
350 Esperion, iHealth, Kaneka, NewAmsterdam, Novartis, Novo Nordisk, Sanofi, and 89bio. He is a
351 co-investigator on a grant funded by Merck. Dr. Martin is a coinventor on a patent application
352 filed by Johns Hopkins University for the Martin/Hopkins method of low-density lipoprotein
353 cholesterol and that patent application has since been abandoned to enable use without
354 intellectual property restrictions. None of the other authors report any conflicts of interest.

355 **Sources of Funding:**

356 Dr. Quispe is supported by an NIH T32 training grant (5T32HL007227). Drs. Michos is
357 supported by the Amato Fund for Women's Cardiovascular Health at Johns Hopkins. The MESA
358 study is supported by contracts HHSN268201500003I, N01-HC-95159, N01-HC-95160, N01-
359 HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166,
360 N01-HC-95167, N01-HC-95168 and N01-HC-95169 from the NIH/NHLBI, by grants UL1-TR-
361 000040, UL1-TR-001079, and UL1-TR-001420 from NCATS. The ancillary data used in this
362 analysis were funded by R01 HL088451. Drs. Ndumele and Michos are additionally supported
363 for this work by an American Heart Association Strategic Focused Research Network Grant
364 20SFRN35120152.

365 **Acknowledgements**

366 The authors thank the other investigators, the staff, and the MESA participants for their valuable
367 contributions. A full list of participating MESA investigators and institutions can be found at
368 <http://www.mesa-nhlbi.org>.

369

370 **REFERENCES**

- 371 1. Fliotsos M, Zhao D, Rao VN, Ndumele CE, Guallar E, Burke GL, Vaidya D, Delaney
372 JCA and Michos ED. Body Mass Index From Early-, Mid-, and Older-Adulthood and Risk of
373 Heart Failure and Atherosclerotic Cardiovascular Disease: MESA. *J Am Heart Assoc.*
374 2018;7:e009599.
- 375 2. Rao VN, Zhao D, Allison MA, Guallar E, Sharma K, Criqui MH, Cushman M,
376 Blumenthal RS and Michos ED. Adiposity and Incident Heart Failure and its Subtypes: MESA
377 (Multi-Ethnic Study of Atherosclerosis). *JACC Heart Fail.* 2018;6:999-1007.
- 378 3. Ndumele CE, Matsushita K, Lazo M, Bello N, Blumenthal RS, Gerstenblith G, Nambi V,
379 Ballantyne CM, Solomon SD, Selvin E, Folsom AR and Coresh J. Obesity and Subtypes of
380 Incident Cardiovascular Disease. *J Am Heart Assoc.* 2016;5.
- 381 4. Ward ZJ, Bleich SN, Cradock AL, Barrett JL, Giles CM, Flax C, Long MW and
382 Gortmaker SL. Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity. *N*
383 *Engl J Med.* 2019;381:2440-2450.
- 384 5. Mandviwala T, Khalid U and Deswal A. Obesity and Cardiovascular Disease: a Risk
385 Factor or a Risk Marker? *Curr Atheroscler Rep.* 2016;18:21.
- 386 6. Quispe R, Martin SS and Jones SR. Triglycerides to high-density lipoprotein-cholesterol
387 ratio, glycemic control and cardiovascular risk in obese patients with type 2 diabetes. *Curr Opin*
388 *Endocrinol Diabetes Obes.* 2016;23:150-6.
- 389 7. Davidson MH. Triglyceride-rich lipoprotein cholesterol (TRL-C): the ugly stepsister of
390 LDL-C. *Eur Heart J.* 2018;39:620-622.
- 391 8. Boren J and Packard CJ. Keeping remnants in perspective. *Eur Heart J.* 2021.

- 392 9. Laufs U, Parhofer KG, Ginsberg HN and Hegele RA. Clinical review on triglycerides.
393 *Eur Heart J.* 2020;41:99-109c.
- 394 10. Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Boren J, Catapano AL, Descamps
395 OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Nordestgaard BG, Ray KK,
396 Reiner Z, Taskinen MR, Tokgozoglul, Tybjaerg-Hansen A, Watts GF and European
397 Atherosclerosis Society Consensus P. Triglyceride-rich lipoproteins and high-density lipoprotein
398 cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for
399 management. *Eur Heart J.* 2011;32:1345-61.
- 400 11. Proctor SD, Vine DF and Mamo JC. Arterial retention of apolipoprotein B(48)- and
401 B(100)-containing lipoproteins in atherogenesis. *Curr Opin Lipidol.* 2002;13:461-70.
- 402 12. Quispe R, Manalac RJ, Faridi KF, Blaha MJ, Toth PP, Kulkarni KR, Nasir K, Virani SS,
403 Banach M, Blumenthal RS, Martin SS and Jones SR. Relationship of the triglyceride to high-
404 density lipoprotein cholesterol (TG/HDL-C) ratio to the remainder of the lipid profile: The Very
405 Large Database of Lipids-4 (VLDL-4) study. *Atherosclerosis.* 2015;242:243-50.
- 406 13. Varbo A, Benn M, Tybjaerg-Hansen A and Nordestgaard BG. Elevated remnant
407 cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated
408 low-density lipoprotein cholesterol causes ischemic heart disease without inflammation.
409 *Circulation.* 2013;128:1298-309.
- 410 14. Varbo A, Benn M, Tybjaerg-Hansen A, Jorgensen AB, Frikke-Schmidt R and
411 Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. *J Am*
412 *Coll Cardiol.* 2013;61:427-436.
- 413 15. Quispe R, Martin SS, Michos ED, Lamba I, Blumenthal RS, Saeed A, Lima JAC, Puri R,
414 Nomura SO, Tsai MY, Wilkins JT, Ballantyne CM, Nicholls SJ, Jones SR and Elshazly MB.

- 415 Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary
416 prevention study. *Eur Heart J*. 2021.
- 417 16. Elshazly MB, Mani P, Nissen S, Brennan DM, Clark D, Martin S, Jones SR, Quispe R,
418 Donnellan E, Nicholls SJ and Puri R. Remnant cholesterol, coronary atheroma progression and
419 clinical events in statin-treated patients with coronary artery disease. *Eur J Prev Cardiol*.
420 2020;27:1091-1100.
- 421 17. D'Souza A M, Neumann UH, Glavas MM and Kieffer TJ. The glucoregulatory actions of
422 leptin. *Mol Metab*. 2017;6:1052-1065.
- 423 18. Hsu WY, Chao YW, Tsai YL, Lien CC, Chang CF, Deng MC, Ho LT, Kwok CF and
424 Juan CC. Resistin induces monocyte-endothelial cell adhesion by increasing ICAM-1 and
425 VCAM-1 expression in endothelial cells via p38MAPK-dependent pathway. *J Cell Physiol*.
426 2011;226:2181-8.
- 427 19. Hansen D, Dendale P, Beelen M, Jonkers RA, Mullens A, Corluy L, Meeusen R and van
428 Loon LJ. Plasma adipokine and inflammatory marker concentrations are altered in obese, as
429 opposed to non-obese, type 2 diabetes patients. *Eur J Appl Physiol*. 2010;109:397-404.
- 430 20. Li S, Shin HJ, Ding EL and van Dam RM. Adiponectin levels and risk of type 2 diabetes:
431 a systematic review and meta-analysis. *Jama*. 2009;302:179-88.
- 432 21. Arita Y, Kihara S, Ouchi N, Maeda K, Kuriyama H, Okamoto Y, Kumada M, Hotta K,
433 Nishida M, Takahashi M, Nakamura T, Shimomura I, Muraguchi M, Ohmoto Y, Funahashi T
434 and Matsuzawa Y. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived
435 growth factor-BB-binding protein and regulates growth factor-induced common postreceptor
436 signal in vascular smooth muscle cell. *Circulation*. 2002;105:2893-8.

- 437 22. Sweeney T, Ogunmoroti O, Ndumele CE, Zhao D, Varma B, Allison MA, Budoff MJ,
438 Fashanu OE, Sharma A, Bertoni AG and Michos ED. Associations of adipokine levels with the
439 prevalence and extent of valvular and thoracic aortic calcification: The Multi-Ethnic Study of
440 Atherosclerosis (MESA). *Atherosclerosis*. 2021;338:15-22.
- 441 23. Varma B, Ogunmoroti O, Ndumele CE, Di Z, Szklo M, Sweeney T, Allison MA, Budoff
442 MJ, Subramanya V, Bertoni AG and Michos ED. Higher Leptin Levels Are Associated with
443 Coronary Artery Calcium Progression: the Multi-Ethnic Study of Atherosclerosis (MESA).
444 *Diabetes Epidemiology and Management*. 2021:100047.
- 445 24. Broni EK, Ogunmoroti O, Quispe R, Sweeney T, Varma B, Fashanu OE, Lutsey PL,
446 Allison M, Szklo M, Ndumele CE and Michos ED. Adipokines and Incident Venous
447 Thromboembolism: The Multi-Ethnic Study of Atherosclerosis. *Journal of Thrombosis and*
448 *Haemostasis*. 2022.
- 449 25. Vella CA, Allison MA, Cushman M, Jenny NS, Miles MP, Larsen B, Lakoski SG,
450 Michos ED and Blaha MJ. Physical Activity and Adiposity-related Inflammation: The MESA.
451 *Med Sci Sports Exerc*. 2017;49:915-921.
- 452 26. Rasmussen-Torvik LJ, Wassel CL, Ding J, Carr J, Cushman M, Jenny N and Allison MA.
453 Associations of body mass index and insulin resistance with leptin, adiponectin, and the leptin-
454 to-adiponectin ratio across ethnic groups: the Multi-Ethnic Study of Atherosclerosis (MESA).
455 *Ann Epidemiol*. 2012;22:705-9.
- 456 27. Martin SS, Blaha MJ, Elshazly MB, Toth PP, Kwiterovich PO, Blumenthal RS and Jones
457 SR. Comparison of a novel method vs the Friedewald equation for estimating low-density
458 lipoprotein cholesterol levels from the standard lipid profile. *JAMA*. 2013;310:2061-8.

- 459 28. Sajja A, Park J, Sathiyakumar V, Varghese B, Pallazola VA, Marvel FA, Kulkarni K,
460 Muthukumar A, Joshi PH, Gianos E, Hirsh B, Mintz G, Goldberg A, Morris PB, Sharma G,
461 Blumenthal RS, Michos ED, Post WS, Elshazly MB, Jones SR and Martin SS. Comparison of
462 Methods to Estimate Low-Density Lipoprotein Cholesterol in Patients With High Triglyceride
463 Levels. *JAMA Netw Open*. 2021;4:e2128817.
- 464 29. Faridi KF, Quispe R, Martin SS, Hendrani AD, Joshi PH, Brinton EA, Cruz DE, Banach
465 M, Toth PP, Kulkarni K and Jones SR. Comparing different assessments of remnant lipoprotein
466 cholesterol: The very large database of lipids. *J Clin Lipidol*. 2019;13:634-644.
- 467 30. Watts GF and Chan DC. Atherogenic Dyslipoproteinemia and Management of ASCVD:
468 Will New Indices Untie the Gordian Knot? *J Am Coll Cardiol*. 2020;75:2136-2139.
- 469 31. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-
470 Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall
471 AR, Brewer B and Investigators I. Effects of torcetrapib in patients at high risk for coronary
472 events. *The New England journal of medicine*. 2007;357:2109-22.
- 473 32. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR,
474 Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK,
475 Tardif JC, Wright RS and dal OI. Effects of dalcetrapib in patients with a recent acute coronary
476 syndrome. *The New England journal of medicine*. 2012;367:2089-99.
- 477 33. Investigators A-H, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-
478 Nickens P, Koprowicz K, McBride R, Teo K and Weintraub W. Niacin in patients with low HDL
479 cholesterol levels receiving intensive statin therapy. *N Engl J Med*. 2011;365:2255-67.
- 480 34. Agerholm-Larsen B, Tybjaerg-Hansen A, Schnohr P, Steffensen R and Nordestgaard BG.
481 Common cholesteryl ester transfer protein mutations, decreased HDL cholesterol, and possible

- 482 decreased risk of ischemic heart disease: The Copenhagen City Heart Study. *Circulation*.
483 2000;102:2197-203.
- 484 35. Agerholm-Larsen B, Nordestgaard BG, Steffensen R, Jensen G and Tybjaerg-Hansen A.
485 Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when
486 caused by a common mutation in the cholesteryl ester transfer protein gene. *Circulation*.
487 2000;101:1907-12.
- 488 36. Nordestgaard BG. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular
489 Disease: New Insights From Epidemiology, Genetics, and Biology. *Circ Res*. 2016;118:547-63.
- 490 37. Quispe R, Martin SS, Michos ED, Lamba I, Blumenthal RS, Saeed A, Lima J, Puri R,
491 Nomura S, Tsai M, Wilkins J, Ballantyne CM, Nicholls S, Jones SR and Elshazly MB. Remnant
492 cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study.
493 *Eur Heart J*. 2021;42:4324-4332.
- 494 38. Komai AM, Musovic S, Peris E, Alrifaiy A, El Hachmane MF, Johansson M, Wernstedt
495 Asterholm I and Olofsson CS. White Adipocyte Adiponectin Exocytosis Is Stimulated via beta3-
496 Adrenergic Signaling and Activation of Epac1: Catecholamine Resistance in Obesity and Type 2
497 Diabetes. *Diabetes*. 2016;65:3301-3313.
- 498 39. Kikai M, Yamada H, Wakana N, Terada K, Yamamoto K, Wada N, Motoyama S, Saburi
499 M, Sugimoto T, Irie D, Kato T, Kawahito H, Ogata T and Matoba S. Adrenergic receptor-
500 mediated activation of FGF-21-adiponectin axis exerts atheroprotective effects in brown adipose
501 tissue-transplanted apoE(-/-) mice. *Biochem Biophys Res Commun*. 2018;497:1097-1103.
- 502 40. Trayhurn P. Hypoxia and adipose tissue function and dysfunction in obesity. *Physiol Rev*.
503 2013;93:1-21.

- 504 41. Fang H and Judd RL. Adiponectin Regulation and Function. *Compr Physiol*.
505 2018;8:1031-1063.
- 506 42. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama
507 N, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Tochino Y, Okutomi K,
508 Horie M, Takeda S, Aoyama T, Funahashi T and Matsuzawa Y. Diet-induced insulin resistance
509 in mice lacking adiponectin/ACRP30. *Nat Med*. 2002;8:731-7.
- 510 43. Kim JY, van de Wall E, Laplante M, Azzara A, Trujillo ME, Hofmann SM, Schraw T,
511 Durand JL, Li H, Li G, Jelicks LA, Mehler MF, Hui DY, Deshaies Y, Shulman GI, Schwartz GJ
512 and Scherer PE. Obesity-associated improvements in metabolic profile through expansion of
513 adipose tissue. *J Clin Invest*. 2007;117:2621-37.
- 514 44. Whitehead JP, Richards AA, Hickman IJ, Macdonald GA and Prins JB. Adiponectin--a
515 key adipokine in the metabolic syndrome. *Diabetes Obes Metab*. 2006;8:264-80.
- 516 45. Kadowaki T and Yamauchi T. Adiponectin and adiponectin receptors. *Endocr Rev*.
517 2005;26:439-51.
- 518 46. Hopkins TA, Ouchi N, Shibata R and Walsh K. Adiponectin actions in the cardiovascular
519 system. *Cardiovasc Res*. 2007;74:11-8.
- 520 47. Chan DC, Watts GF, Ng TW, Uchida Y, Sakai N, Yamashita S and Barrett PH.
521 Adiponectin and other adipocytokines as predictors of markers of triglyceride-rich lipoprotein
522 metabolism. *Clin Chem*. 2005;51:578-85.
- 523 48. Kazumi T, Kawaguchi A, Hirano T and Yoshino G. Serum adiponectin is associated with
524 high-density lipoprotein cholesterol, triglycerides, and low-density lipoprotein particle size in
525 young healthy men. *Metabolism*. 2004;53:589-93.

- 526 49. Komatsu M, Ohfusa H, Aizawa T and Hashizume K. Adiponectin inversely correlates
527 with high sensitive C-reactive protein and triglycerides, but not with insulin sensitivity, in
528 apparently healthy Japanese men. *Endocr J.* 2007;54:553-8.
- 529 50. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M,
530 Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai
531 R, Kahn BB and Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation
532 by activating AMP-activated protein kinase. *Nat Med.* 2002;8:1288-95.
- 533 51. Combs TP, Pajvani UB, Berg AH, Lin Y, Jelicks LA, Laplante M, Nawrocki AR, Rajala
534 MW, Parlow AF, Cheeseboro L, Ding YY, Russell RG, Lindemann D, Hartley A, Baker GR,
535 Obici S, Deshaies Y, Ludgate M, Rossetti L and Scherer PE. A transgenic mouse with a deletion
536 in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved
537 insulin sensitivity. *Endocrinology.* 2004;145:367-83.
- 538 52. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T,
539 Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman
540 ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M,
541 Froguel P and Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance
542 associated with both lipodystrophy and obesity. *Nat Med.* 2001;7:941-6.
- 543 53. Boden G, Chen X, Mozzoli M and Ryan I. Effect of fasting on serum leptin in normal
544 human subjects. *J Clin Endocrinol Metab.* 1996;81:3419-23.
- 545 54. Wu Y, Fortin DA, Cochrane VA, Chen PC and Shyng SL. NMDA receptors mediate
546 leptin signaling and regulate potassium channel trafficking in pancreatic beta-cells. *J Biol Chem.*
547 2017;292:15512-15524.

- 548 55. Dunmore SJ and Brown JE. The role of adipokines in beta-cell failure of type 2 diabetes.
549 *J Endocrinol.* 2013;216:T37-45.
- 550 56. Soedling H, Hodson DJ, Adrianssens AE, Gribble FM, Reimann F, Trapp S and Rutter
551 GA. Limited impact on glucose homeostasis of leptin receptor deletion from insulin- or
552 proglucagon-expressing cells. *Mol Metab.* 2015;4:619-30.
- 553 57. Martin SS, Blaha MJ, Muse ED, Qasim AN, Reilly MP, Blumenthal RS, Nasir K, Criqui
554 MH, McClelland RL, Hughes-Austin JM and Allison MA. Leptin and incident cardiovascular
555 disease: the Multi-ethnic Study of Atherosclerosis (MESA). *Atherosclerosis.* 2015;239:67-72.
- 556 58. Dutheil F, Gordon BA, Naughton G, Crendal E, Courteix D, Chaplais E, Thivel D, Lac G
557 and Benson AC. Cardiovascular risk of adipokines: a review. *J Int Med Res.* 2018;46:2082-2095.
- 558 59. Barnes PJ and Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic
559 inflammatory diseases. *N Engl J Med.* 1997;336:1066-71.
- 560 60. Chiba T, Nakazawa T, Yui K, Kaneko E and Shimokado K. VLDL induces adipocyte
561 differentiation in ApoE-dependent manner. *Arterioscler Thromb Vasc Biol.* 2003;23:1423-9.
562
563

564
565
566
567

TABLES

Table 1 – Baseline characteristics by tertiles of adiponectin (n=1,791)

	Lowest Tertile	Second Tertile	Highest Tertile	p-value
Age, years	62.2 ± 9.2	64.5 ± 9.5	66.8 ± 9.5	0.591
Female	210 (35.2)	300 (50.3)	421 (70.5)	<0.001
Race/ethnicity				<0.001
White	158 (26.5)	225 (37.7)	330 (55.3)	
Chinese-American	119 (19.9)	71 (11.9)	53 (8.9)	
Black	171 (28.6)	115 (19.3)	92 (15.4)	
Hispanic	149 (25.0)	186 (31.2)	122 (20.4)	
Smoking status				0.023
Never	265 (44.4)	272 (45.6)	302 (50.6)	
Former	246 (41.2)	258 (43.2)	242 (40.5)	
Current	86 (14.4)	67 (11.2)	53 (8.9)	
BMI, kg/m²	29.0 ± 5.0	28.2 ± 4.9	26.4 ± 4.8	0.523
SBP, mmHg	124.2 ± 20.5	123.6 ± 19.9	123.3 ± 22.1	0.031
Triglycerides, mg/dl	130 (93-180)	117 (81-164)	89 (65-136)	<0.001
RC, mg/dl	23.6 (19.1-30.2)	22.3 (17.3-28.8)	18.8 (15-24.9)	<0.001
Total Cholesterol, mg/dl	185.6 ± 36.0	191.0 ± 34.6	193.5 ± 35.4	0.632
LDL-C, mg/dl	115.1 ± 31.1	115.5 ± 30.2	112.5 ± 30.7	0.764
HDL-C, mg/dL	44.8 ± 11.2	51.3 ± 13.2	60.0 ± 16.8	<0.001
Diabetes	112 (18.8)	72 (12.1)	54 (9.1)	<0.001
Antihypertensive medications	251 (43.3)	244 (42)	246 (42.3)	0.901
Lipid-lowering medications	147 (25.3)	152 (26.2)	133 (22.9)	0.406

568 Values are shown using mean ±SD for normal and median (25th-75th percentile) for not-normal
569 continuous variables, and n(%) for categorical variables.

570 Comparison was made using chi-square (categorical), t-test (normal) or Kruskal-Wallis (not-
571 normal). **Bold** values are statistically significant (p<0.05)

572 BMI: body mass index, SBP: systolic blood pressure, RC: remnant cholesterol; LDL-C: low-
573 density lipoprotein cholesterol, HDL-C: high-density lipoprotein cholesterol

574 **Table 2 – Baseline characteristics by tertiles of leptin (n=1,791)**
 575

	First Tertile	Second Tertile	Third Tertile	p-value
Age, years	64.3 ± 9.9	64.3 ± 9.9	65.0 ± 9.2	0.177
Female	125 (20.9)	295 (49.4)	511 (85.6)	<0.001
Race/ethnicity				<0.001
White	266 (44.6)	254 (42.6)	193 (32.3)	
Chinese-American	126 (21.1)	82 (13.7)	35 (5.9)	
Black	76 (12.7)	110 (18.4)	192 (32.2)	
Hispanic	129 (21.6)	151 (25.3)	177 (29.6)	
Smoking status				<0.001
Never	231 (38.7)	298 (49.9)	310 (51.9)	
Former	280 (46.9)	235 (39.4)	231 (38.7)	
Current	86 (14.4)	64 (10.7)	56 (9.4)	
BMI, kg/m²	24.8 ± 3.2	27.2 ± 3.6	31.5 ± 5.4	<0.001
SBP, mmHg	120.0 ± 19.7	123.1 ± 20.0	127.9 ± 22.0	0.013
Triglycerides, mg/dl	100 (69-141)	118 (83-165)	121 (83-177)	<0.001
RC, mg/dl	20 (15.7-25.4)	22.4 (17.4-28.3)	22.8 (17.8-30)	<0.001
Total Cholesterol, mg/dl	185.5 ± 33.8	190.2 ± 36.0	194.4 ± 36.1	0.204
LDL-C, mg/dl	111.7 ± 29.2	114.4 ± 31.2	117.1 ± 31.4	0.154
HDL-C, mg/dL	51.8 ± 16.2	51.7 ± 15.7	52.6 ± 13.8	<0.001
Diabetes	64 (10.7)	80 (13.4)	94 (15.8)	0.037
Antihypertensive medications	186 (31.9)	246 (42.3)	309 (53.7)	<0.001
Lipid-lowering medications	115 (19.7)	164 (28.2)	153 (26.5)	0.002

576 Values are shown using mean ±SD for normal and median (25th-75th percentile) for not-normal
 577 continuous variables, and n(%) for categorical variables.
 578 Comparison was made using chi-square (categorical), t-test (normal) or Kruskal-Wallis (not-
 579 normal). **Bold** values are statistically significant (p<0.05)

580
 581

582 **Table 3 – Baseline characteristics by tertiles of resistin (n=1,791)**
 583

	First Tertile	Second Tertile	Third Tertile	p-value
Age, years	62.8 ± 9.0	64.0 ± 9.5	66.8 ± 9.7	0.139
Female	307 (51.4)	292 (48.9)	332 (55.6)	0.065
Race/ethnicity				<0.001
White	209 (35.0)	278 (46.6)	226 (37.9)	
Chinese-American	105 (17.6)	64 (10.7)	74 (12.4)	
Black	122 (20.4)	103 (17.3)	153 (25.6)	
Hispanic	161 (27.0)	152 (25.5)	144 (24.1)	
Smoking status				0.068
Never	298 (49.9)	263 (44.1)	278 (46.6)	
Former	242 (40.5)	249 (41.7)	255 (42.7)	
Current	57 (9.6)	85 (14.2)	64 (10.7)	
BMI, kg/m²	27.1 ± 4.7	28.1 ± 4.8	28.4 ± 5.4	0.002
SBP, mmHg	122.3 ± 20.4	122.1 ± 20.5	126.6 ± 21.3	0.550
Triglycerides, mg/dl	109 (76-149)	113 (76-164)	117 (80-171)	0.0371
RC, mg/dl	21.4 (16.6-26.3)	21.9 (16.7-28)	22 (17.3-28.9)	0.1222
Total Cholesterol, mg/dl	194.3 ± 35.8	188.4 ± 33.8	187.4 ± 36.6	0.144
LDL-C, mg/dl	117.2 ± 31.1	112.7 ± 30.1	113.2 ± 30.7	0.762
HDL-C, mg/dL	54.1 ± 16.3	52.0 ± 14.9	50.1 ± 14.2	0.003
Diabetes	63 (10.6)	75 (12.6)	100 (16.8)	0.006
Antihypertensive medications	210 (36.3)	238 (40.8)	293 (50.6)	<0.001
Lipid-lowering medications	141 (24.4)	156 (26.7)	135 (23.3)	0.388

584 Values are shown using mean ±SD for normal and median (25th-75th percentile) for not-normal
 585 continuous variables, and n(%) for categorical variables.
 586 Comparison was made using chi-square (categorical), t-test (normal) or Kruskal-Wallis (not-
 587 normal). **Bold** values are statistically significant (p<0.05)
 588

589 **Table 4. Linear regression models for associations between baseline adipokines and levels**
 590 **of RC (n=1,791)**
 591

	Model 1	Model 2	Model 3	Model 4	Model 5	Model 6	Model 7	Model 8
Adiponectin	-17.2 (-19.6, -14.6)	-17.1 (-19.5, -14.6)	-15.4 (-17.9, -12.8)	-15.0 (-17.3, -12.6)	-14.6 (-16.8, -12.0)	-14.6 (-16.9, -12.2)	-13.6 (-16.0, -11.1)	-10.2 (-12.5, -7.8)
Leptin	7.7 (5.9, 9.6)	7.9 (6.0, 9.7)	5.1 (2.8, 7.5)	4.8 (2.7, 7.0)	4.5 (2.3, 6.6)	4.8 (2.7, 7.0)	2.6 (0.5, 4.6)	2.3 (1.0, 3.6)
Resistin	6.0 (1.6, 10.5)	5.6 (1.2, 10.1)	3.6 (-0.6, 8.0)	4.4 (0.5, 8.4)	5.1 (1.2, 9.2)	4.0 (0.2, 8.1)	3.6 (-0.7, 8.1)	3.4 (-0.3, 7.2)

592 RC and adipokines levels were log-transformed. Results shown are shown as percent differences

593 $[(\epsilon^{\beta}-1)*100]$. **Bold** values are statistically significant ($p<0.05$)

594 Model 1 – age, sex, race/ethnicity, and study site.

595 Model 2 – Model 1 + education, smoking status, and physical activity

596 Model 3 – Model 2 + BMI

597 Model 4 – Model 3 + LDL-C

598 Model 5 – Model 4 + use of lipid-lowering therapy

599 Model 6 – Model 5 + diabetes mellitus

600 Model 7 - Model 6 + subcutaneous fat area, in cm^2 (instead of BMI)

601 Model 8 – Model 6 + visceral fat area, in cm^2 (instead of BMI)

602

603 **Table 5. Mixed-model (longitudinal) analyses for associations between baseline adipokines**
 604 **and levels of RC**
 605

	Model 1	Model 2	Model 3	Model 4	Model 5	Model 6	Model 7	Model 8
Adiponectin	-14.1 (-16.3, -11.9)	-14.2 (-16.4, -12.0)	-12.0 (-14.2, -9.7)	-12.1 (-14.1, -10.1)	-11.9 (-13.9, -9.8)	-11.6 (-13.6, -9.5)	-12.7 (-14.9, -10.4)	-9.9 (-11.9, -7.9)
Leptin	6.4 (4.8, 8.0)	6.5 (4.9, 8.1)	1.5 (-0.2, 3.3)	2.0 (0.4, 3.6)	1.9 (0.3, 3.5)	1.8 (0.2, 3.4)	6.6 (4.5, 8.6)	0.2 (-1.3, 1.7)
Resistin	4.5 (0.7, 8.3)	4.1 (0.4, 7.9)	1.8 (-1.8, 5.5)	3.0 (-0.2, 6.4)	3.2 (-0.1, 6.5)	2.8 (-0.4, 6.2)	4.0 (0.3, 7.8)	3.6 (0.5, 6.8)

606 RC and adipokines levels were log-transformed. Results shown are shown as percent differences
 607 $[(\epsilon^\beta - 1) * 100]$. **Bold** values are statistically significant ($p < 0.05$)

608 Model 1 – age, sex, race/ethnicity, and study site.

609 Model 2 – Model 1 + education, smoking status, and physical activity

610 Model 3 – Model 2 + BMI

611 Model 4 – Model 3 + LDL-C

612 Model 5 – Model 4 + use of lipid-lowering therapy

613 Model 6 – Model 5 + diabetes mellitus

614 Model 7 - Model 6 + subcutaneous fat area, in cm^2 (instead of BMI)

615 Model 8 – Model 6 + visceral fat area, in cm^2 (instead of BMI)

616

617 Time-varying variables were age, smoking status, BMI, LDL-C and use of lipid-lowering therapy

618

619


620

621

622
623
624
625
626


FIGURES

Figure 1. Adiponectin vs. RC levels (log-transformed). Regression line with 95% CI is displayed.




627
628
629

630 **Figure 2.** Leptin vs. RC levels (log-transformed). Regression line with 95% CI is displayed.
631



632
633

634 **Figure 3.** Resistin vs. RC levels (log-transformed). Regression line with 95% CI is displayed.
635



636
637
638